The new diagnostic tool moves beyond the limited genomic snapshots characteristic of traditional screening methods. By analyzing the full breadth of DNA and RNA patterns, Caris Detect seeks to establish a new clinical standard for identifying subtle biological signals. David Dean Halbert, founder and CEO of Caris Life Sciences, described the platform as a significant advancement in molecular science, intended to provide physicians with more granular data for informed decision-making.
In section Releases
Caris Life Sciences Targets Early Cancer Detection with New Blood Test
Irving-based Caris Life Sciences has launched Caris Detect, a multi-cancer early detection blood test utilizing ultra-deep whole genome and transcriptome sequencing. By integrating proprietary artificial intelligence with an expansive database of over one million clinical cases, the company aims to identify malignancy markers at earlier, more treatable stages.
Performance claims for the test are backed by the ACHIEVE 1 study, which assessed the platform's ability to detect cancer signals across diverse types of disease. The underlying AI models leverage a dataset containing more than 50 billion molecular markers, allowing the system to distinguish early-stage pathological patterns from healthy biological noise. Caris intends to continue refining the platform through ongoing research to expand its clinical utility and diagnostic accuracy.
Comments (0)
No comments yet. Be the first!